申请人:Merck, Sharp & Dohme Ltd.
公开号:US05612336A1
公开(公告)日:1997-03-18
Compounds of formula (I), and salts and prodrugs thereof, wherein Q.sup.1 is phenyl substituted by one or more halo; optionally substituted naphthyl, indolyl, benzothiophenyl, benzofuranyl, benzyl or fluorenyl; the dotted line represents an optional covalent bond; one of X and Y is H and the other is hydroxy or C.sub.1-6 alkoxy, or X and Y together form a group .dbd.O or .dbd.NOR.sup.5 where R.sup.5 is H or C.sub.1-6 alkyl; R.sup.1 is H or C.sub.1-6 alkyl. R.sup.2 is CO--W--R.sup.6 where W represents a bond or a hydrocarbon chain of 1-6 carbon atoms and R.sup.6 is an azacyclic or azabicyclic group; R.sup.3 is H, C.sub.1-6 alkyl or C.sub.2-6 alkenyl; and R.sup.4 is phenyl optionally substituted by 1-3 of C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, OR.sup.a, SR.sup.a, SOR.sup.a, NR.sup.a R.sup.b, NR.sup.a COR.sup.b, NR.sup.a CO.sub.2 R.sup.b, CO.sub.2 R.sup.a or CONR.sup.a R.sup.b, where R.sup.a and R.sup.b are H, C.sub.1-6 alkyl, phenyl or trifluoromethyl; are tachykinin antagonists useful in therapy.
公式(I)的化合物,以及其盐和前药,其中Q1为苯基,取代一个或多个卤素; 可选取代萘基,吲哚基,苯并噻吩基,苯并呋喃基,苄基或芴基; 虚线表示可选的共价键; X和Y中的一个为H,另一个为羟基或C1-6烷氧基,或者X和Y在一起形成一个基团.dbd.O或.dbd.NOR5,其中R5为H或C1-6烷基; R1为H或C1-6烷基。 R2为CO-W-R6,其中W表示1-6个碳原子的键或碳氢链,R6为氮杂环或氮杂双环基团; R3为H,C1-6烷基或C2-6烯基; R4为苯基,可选取代1-3个C1-6烷基,C2-6烯基,C2-6炔基,卤素,氰基,硝基,三氟甲基,三甲基硅基,ORa,SRa,SORa,NRaRb,NRaCORb,NRaCO2Rb,CO2Ra或CONRaRb,其中Ra和Rb为H,C1-6烷基,苯基或三氟甲基; 是治疗中有用的缩短肽拮抗剂。